← Back to Search

Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer.

N/A

Waitlist Available

Led By Bilal Chughtai, MD

Research Sponsored by Northwell Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 1 year

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing Urolift, a procedure that uses small implants to keep the urinary passage open, on patients who have urinary issues after radiation therapy. The implants help urine flow more easily by holding the passage open, which may reduce symptoms like frequent or painful urination. The UroLift® System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH), which opens the urethra by retracting obstructing prostatic lobes without incisions or thermal injury.

Eligible Conditions

Enlarged Prostate

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at baseline and one year post treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at baseline and one year post treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and at baseline and one year post treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in IIEF score through study completion, an average of 1 year

Change in IPSS scores from baseline and one year post treatment

Change in MSHQ through study completion, an average of 1 year

+3 more

Secondary study objectives

Change in medication usage through study completion, an average of 1 year

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: UroliftExperimental Treatment1 Intervention

This is a single-arm study involving 1 year of follow-up. Study intervention involves a one-time administration of Urolift prior to SBRT for prostate cancer treatment.

Do I qualify?Apply below to find out